Fulgent Genetics Inc. (FLGT)
NASDAQ: FLGTHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
FLGT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $565.99M
- EPS (TTM)
- -$2.94
- Dividend yield
- None
- 52-week range
- 13.46 – 31.04
- Day range
- 19.90 – 20.70
- Volume / Avg
- 293.94K / 298.25K
- Beta
- —
- Shares outstanding
- 27.52M
- Next earnings
- Nov 6, 2026
52-week range
FLGT stock today
On Oct 7, FLGT ended the session at $20.57, shedding $0.01 (0.05%), versus the S&P 500's 0.22% decline. Shares are 33.7% below their 52-week high of $31.04, set on Nov 25, 2025 and 52.8% above the 52-week low of $13.46, in the middle of the past year's range. FLGT is down 21.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 9.1%.
Fulgent Genetics has posted a net loss over the last twelve months (EPS of -$2.94), so its P/E ratio is not meaningful. Fulgent Genetics's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Fulgent Genetics
Company profileFulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Ming Hsieh
- Headquarters
- El Monte, CA
- Employees
- 1,315
- IPO year
- 2016
- Website
- fulgentgenetics.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$19.00-7.63%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
- EPS estimate
- $1.00
Fulgent Genetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| YDESYD Bio Limited | 5.88 | -4.39% | $416.49M | vs FLGT |
| BDSXBiodesix Inc. | 26.42 | -5.51% | $278.76M | vs FLGT |
| TLSITriSalus Life Sciences Inc. | 4.25 | -0.47% | $261.69M | vs FLGT |
| XGNExagen Inc. | 8.30 | +1.34% | $201.07M | vs FLGT |
| BNRBurning Rock Biotech Limited ADR | 15.18 | -5.77% | $160.09M | vs FLGT |
| CSTLCastle Biosciences Inc. | 33.00 | -1.08% | $1.01B | vs FLGT |
| LMRILumexa Imaging Holdings Inc. | 10.59 | -1.12% | $1.02B | vs FLGT |
| KEQUKewaunee Scientific Corporation | 33.84 | +0.53% | $97.98M | vs FLGT |
Indexes, lists and sector
Fulgent Genetics stock FAQ
What is Fulgent Genetics's stock price today?
FLGT last traded at $20.57 as of Oct 7, 4:00 PM EDT, down 0.05% on the day. Prices are delayed at least 15 minutes.
When is Fulgent Genetics's next earnings date?
Fulgent Genetics is expected to report earnings on Friday, November 6, 2026. Analysts expect EPS of $1.00.
Who is Fulgent Genetics's CEO?
Mr. Ming Hsieh is the chief executive officer of Fulgent Genetics Inc., which has about 1,315 employees.
What is the FLGT 52-week high?
The 52-week high for FLGT is $31.04 and the 52-week low is $13.46. The stock is currently 33.7% below its high.